CN1968922A - 因子xa抑制剂 - Google Patents

因子xa抑制剂 Download PDF

Info

Publication number
CN1968922A
CN1968922A CNA2005800190908A CN200580019090A CN1968922A CN 1968922 A CN1968922 A CN 1968922A CN A2005800190908 A CNA2005800190908 A CN A2005800190908A CN 200580019090 A CN200580019090 A CN 200580019090A CN 1968922 A CN1968922 A CN 1968922A
Authority
CN
China
Prior art keywords
chloro
methyl
thiophene
phenyl
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800190908A
Other languages
English (en)
Chinese (zh)
Inventor
冰-扬·朱
肖恩·M·鲍尔
贾照中
加里·D·普罗布斯特
张燕晨
罗伯特·M·斯卡伯勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN1968922A publication Critical patent/CN1968922A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800190908A 2004-06-18 2005-06-20 因子xa抑制剂 Pending CN1968922A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58089904P 2004-06-18 2004-06-18
US60/580,899 2004-06-18

Publications (1)

Publication Number Publication Date
CN1968922A true CN1968922A (zh) 2007-05-23

Family

ID=35782278

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800190908A Pending CN1968922A (zh) 2004-06-18 2005-06-20 因子xa抑制剂

Country Status (13)

Country Link
US (3) US7521470B2 (enExample)
EP (1) EP1893572B1 (enExample)
JP (1) JP5020073B2 (enExample)
KR (1) KR101195801B1 (enExample)
CN (1) CN1968922A (enExample)
AU (1) AU2005257999B2 (enExample)
BR (1) BRPI0512273A (enExample)
CA (1) CA2565437A1 (enExample)
IL (1) IL178807A0 (enExample)
MX (1) MXPA06013960A (enExample)
NZ (1) NZ552187A (enExample)
WO (1) WO2006002099A2 (enExample)
ZA (1) ZA200610138B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219753A (zh) * 2011-04-21 2011-10-19 山东大学 一种三氮唑类化合物及其制备方法与应用
CN102762550A (zh) * 2009-12-17 2012-10-31 米伦纽姆医药公司 Xa因子抑制剂的盐和结晶形式
CN104045634A (zh) * 2014-06-06 2014-09-17 浙江工业大学 含二氟甲基吡唑甲酰胺类化合物及其制备方法和用途
CN115715189A (zh) * 2020-03-23 2023-02-24 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
CN118221605A (zh) * 2022-12-20 2024-06-21 浙江省化工研究院有限公司 一类含异噁唑啉类化合物、其制备方法及应用

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
JP5020073B2 (ja) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク. 第Xa因子阻害剤
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
WO2007007588A1 (ja) * 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
WO2007087442A2 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
CN103554095A (zh) 2006-02-15 2014-02-05 Abbvie公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
US20090186810A1 (en) * 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EA015942B1 (ru) * 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
US20080242694A1 (en) * 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
CA2666922A1 (en) 2006-10-25 2008-05-02 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamides
PT2077995E (pt) * 2006-11-02 2012-05-10 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
EP2114930A2 (en) * 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN101743001B (zh) * 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
NZ599556A (en) * 2007-05-02 2013-10-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
CA2713139C (en) 2008-02-01 2013-04-23 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
PE20091653A1 (es) * 2008-03-26 2009-11-14 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
US20110071197A1 (en) * 2008-04-16 2011-03-24 Peter Nilsson Bis-aryl compounds for use as medicaments
JP5627574B2 (ja) * 2008-06-03 2014-11-19 インターミューン, インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
US8394964B2 (en) 2009-12-17 2013-03-12 Millennium Pharmaceuticals, Inc. Methods of synthesizing factor Xa inhibitors
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
ES2626601T3 (es) 2010-06-28 2017-07-25 Bayer Intellectual Property Gmbh Compuestos heterocíclicos como pesticidas
AR082803A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
US20150224091A1 (en) 2011-08-31 2015-08-13 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
ES2716008T3 (es) 2012-07-18 2019-06-07 Sunshine Lake Pharma Co Ltd Derivados heterocíclicos nitrogenados y su aplicación en fármacos
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014089364A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc Histone demethylase inhibitors
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2015172196A1 (en) * 2014-05-13 2015-11-19 Monash University Heterocyclic compounds and use of same
EP3268360B1 (en) 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactams as inhibitors of rock
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
AR109304A1 (es) 2016-08-10 2018-11-21 Sumitomo Chemical Co Compuesto de oxadiazol y su uso
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
AR119774A1 (es) * 2019-08-19 2022-01-12 Pi Industries Ltd Compuestos de oxadiazol que contienen un anillo heteroaromático de 5 miembros para controlar o prevenir hongos fitopatogénicos
CN118496197A (zh) 2019-12-20 2024-08-16 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
EP4077317B1 (en) 2019-12-20 2024-06-26 Bayer Aktiengesellschaft Thienyloxazolones and analogues
WO2021207031A1 (en) * 2020-04-05 2021-10-14 Coagulo Medical Technologies, Inc. Methods of treating and preventing coronavirus infections using inhibitors of coagulation factor xa
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
EP4393919A1 (en) * 2022-12-27 2024-07-03 Exscientia Al Limited Lsd1 modulators
AR132248A1 (es) * 2023-03-29 2025-06-11 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos para su uso

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
CA2151044A1 (en) 1992-12-15 1994-06-23 Terence K. Brunck Novel inhibitors for factor xa
NZ296210A (en) 1994-12-02 1998-05-27 Yamanouchi Pharma Co Ltd Amidinonaphthyl derivatives to inhibit activated blood coagulation factor x
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
CN1246847A (zh) 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1020434A4 (en) 1997-08-27 2000-11-15 Kissei Pharmaceutical 3-AMIDINOANILINE DERIVATIVES, INHIBITORS OF THE ACTIVATED BLOOD COINTENANCE FACTOR X AND INTERMEDIATE PRODUCTS FOR PRODUCING BOTH
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
JP2000178243A (ja) * 1998-12-14 2000-06-27 Teijin Ltd ビフェニルアミジン誘導体
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ES2254385T3 (es) * 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
ES2180456B1 (es) 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
US6914058B2 (en) 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
US20050171358A1 (en) * 2002-03-07 2005-08-04 Noriko Shimozono Substituted isoxazole alkylamine derivative and agri-and horticultural fungicide
JP3090812U (ja) * 2002-06-18 2002-12-26 アルプス電気株式会社 高周波モジュール
EP1616862A4 (en) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF
WO2004101531A1 (en) 2003-04-29 2004-11-25 Dr. Reddy's Laboratories Ltd. Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
WO2004106329A2 (en) 2003-06-03 2004-12-09 Dr. Reddy's Laboratories Ltd. Novel antiinfective compounds and their pharmaceutical compositions
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
CN1886398A (zh) * 2003-10-09 2006-12-27 米伦纽姆医药公司 作为Xa因子抑制剂的经硫醚取代的苯甲酰胺
WO2005035528A2 (en) 2003-10-14 2005-04-21 Dr. Reddy's Laboratories Ltd. Triazole derivatives as antibacterial agents
WO2005082892A2 (en) 2004-02-17 2005-09-09 Dr. Reddy's Laboratories Ltd. Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
JP5020073B2 (ja) 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク. 第Xa因子阻害剤
JP2008528691A (ja) 2005-02-02 2008-07-31 ビテ ファーマシューティカルズ, インコーポレイテッド レニン阻害剤としての1−アシルアミノ−2−ヒドロキシ−3−アミノ−ω−アリールアルカン
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
AR057976A1 (es) 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
JP2007060967A (ja) 2005-08-30 2007-03-15 Tokyo Institute Of Technology 遺伝子多型の検出方法および薬物のスクリーニング方法
US8058284B2 (en) 2005-11-03 2011-11-15 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
RU2440986C2 (ru) * 2005-11-08 2012-01-27 Милленниум Фамэсьютикэлс, Инк. СОЛЬ ИНГИБИТОРА ФАКТОРА Ха, СПОСОБ ЕЕ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ, СОСТОЯЩИЕ ИЗ НАЗВАННОЙ КОМПОЗИЦИИ ТАБЛЕТКА, КАПСУЛА И ЛЕПЕШКА, СПОСОБ ЛЕЧЕНИЯ ТРОМБОЗА И СПОСОБ ИНГИБИРОВАНИЯ КОАГУЛЯЦИИ ОБРАЗЦОВ КРОВИ
US20090186810A1 (en) 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EA015942B1 (ru) 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
DE102006025314A1 (de) 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
US20080051578A1 (en) 2006-08-24 2008-02-28 Georg Dahmann Substituted biaryls, process for their manufacture and use thereof as medicaments
NZ578180A (en) * 2006-12-08 2012-02-24 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
EP2114930A2 (en) * 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN101743001B (zh) * 2007-04-13 2013-02-06 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
NZ599556A (en) * 2007-05-02 2013-10-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762550A (zh) * 2009-12-17 2012-10-31 米伦纽姆医药公司 Xa因子抑制剂的盐和结晶形式
CN102762550B (zh) * 2009-12-17 2015-04-01 米伦纽姆医药公司 Xa因子抑制剂的盐和结晶形式
CN102219753A (zh) * 2011-04-21 2011-10-19 山东大学 一种三氮唑类化合物及其制备方法与应用
CN104045634A (zh) * 2014-06-06 2014-09-17 浙江工业大学 含二氟甲基吡唑甲酰胺类化合物及其制备方法和用途
CN115715189A (zh) * 2020-03-23 2023-02-24 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
CN115715189B (zh) * 2020-03-23 2026-02-13 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
CN118221605A (zh) * 2022-12-20 2024-06-21 浙江省化工研究院有限公司 一类含异噁唑啉类化合物、其制备方法及应用

Also Published As

Publication number Publication date
US8377974B2 (en) 2013-02-19
US20090298806A1 (en) 2009-12-03
US20060100193A1 (en) 2006-05-11
EP1893572A4 (en) 2010-09-08
US20120178733A1 (en) 2012-07-12
WO2006002099A2 (en) 2006-01-05
BRPI0512273A (pt) 2008-02-19
WO2006002099A3 (en) 2006-05-04
AU2005257999A1 (en) 2006-01-05
EP1893572A2 (en) 2008-03-05
IL178807A0 (en) 2007-03-08
EP1893572B1 (en) 2016-12-14
KR101195801B1 (ko) 2012-11-05
CA2565437A1 (en) 2006-01-05
US8153670B2 (en) 2012-04-10
AU2005257999B2 (en) 2011-12-08
KR20070027714A (ko) 2007-03-09
JP5020073B2 (ja) 2012-09-05
MXPA06013960A (es) 2007-03-15
ZA200610138B (en) 2007-12-27
US7521470B2 (en) 2009-04-21
JP2008503497A (ja) 2008-02-07
NZ552187A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
CN1272316C (zh) 苯甲酰胺和相关的因子Xa抑制剂
JP5020073B2 (ja) 第Xa因子阻害剤
CN1143855C (zh) 作为抗凝剂的邻氨基苯甲酰胺衍生物
CN1033088C (zh) 新的噻唑基苯并呋喃衍生物的制备方法
CN1130355C (zh) 调理内皮肽活性的噻吩基-、呋喃基-、吡咯基-与联苯磺酰胺及其衍生物
CN1195762C (zh) 新的2-(亚氨基甲基)氨基-苯基衍生物、其制备、作为药物的应用以及含有它们的药物组合物
CN1390206A (zh) 因子Xa的抑制剂
CN1070173C (zh) 用作药物的苯甲酰基胍衍生物
CN1278793A (zh) 磺酰基衍生物
CN1059142A (zh) 新的噻吩衍生物
CN1192739A (zh) N-杂芳基吡啶磺酰胺衍生物及其作为内皮素拮抗剂的用途
CN1909902A (zh) 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物
CN1359380A (zh) 二氨基噻唑和它们在抑制蛋白激酶中的用法
CN1642938A (zh) 新化合物
CN1674892A (zh) 杂联芳基衍生物作为基质金属蛋白酶抑制剂
CN1491207A (zh) 酰化的二氢化茚基胺及其作为药物的用途
CN1751044A (zh) 用作pepck抑制剂的磺酰胺取代的黄嘌呤
CN1337952A (zh) 作为基质金属蛋白酶抑制剂的2,3,4,5-四氢-1h-[1,4]苯并二氮杂草-3-异羟肟酸
CN1620434A (zh) 作为因子Xa抑制剂的吡咯烷-2-酮类
CN1509278A (zh) N-苯基芳基磺酰胺化合物、包括该化合物作为活性成分的药物组合物、该化合物的合成中间体及其制备方法
CN1639158A (zh) 用作npy受体拮抗剂的噻唑衍生物
CN1551769A (zh) 被取代的8-芳基喹啉磷酸二酯酶-4抑制剂
CN101068797A (zh) 含有噻唑环的羧酸衍生物及其药物用途
CN1333766A (zh) 取代的(氨基亚氨基甲基或氨基甲基)苯并杂芳基化合物
CN1639155A (zh) 吡咯烷噁二唑及噻二唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070523